Welcome to our dedicated page for Context Therapeutics SEC filings (Ticker: CNTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Context Therapeutics Inc. (CNTX) SEC filings page on Stock Titan provides access to the company’s public regulatory documents, including current reports on Form 8-K and other filings made with the U.S. Securities and Exchange Commission. These filings offer detailed insight into how Context describes its business as a clinical-stage biopharmaceutical company advancing T cell engaging (TCE) bispecific antibodies for solid tumors, along with information on its capital markets activity and Nasdaq listing status.
Recent Forms 8-K furnished by Context include clinical and corporate updates tied to its TCE pipeline. For example, the company has reported Phase 1 dose-escalation progress for CTIM-76, a Claudin 6 x CD3 TCE in patients with ovarian, endometrial, or testicular cancer, and CT-95, a Mesothelin x CD3 TCE in patients with pancreatic, non-small cell lung, ovarian, mesothelioma, and colorectal cancers. Filings also describe CT-202, a Nectin-4 x CD3 TCE in preclinical development, and summarize safety observations, preliminary anti-tumor activity, and planned next steps as of the filing dates.
Other 8-Ks detail capital raising arrangements, such as an at-the-market Sales Agreement and its amendment, including aggregate offering limits, use of proceeds for research and development, working capital, and general corporate purposes, and the agent’s commission structure. Additional filings address Nasdaq minimum bid price notifications, extensions, and the company’s subsequent return to compliance, which are relevant for understanding listing risk and trading status.
On Stock Titan, these filings are paired with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify clinical trial disclosures, financing terms, and listing-related updates. Users can review new CNTX filings as they appear in EDGAR, then rely on AI-generated overviews to navigate complex regulatory language and focus on the sections most relevant to their analysis.
Context Therapeutics Inc. reports the resolution of a Delaware stockholder class action challenging parts of its charter. The Court of Chancery previously determined that charter provisions giving directors three-year terms and removal only for cause were invalid, and the company filed a Certificate of Correction to remove them.
Under a new letter agreement, a third-party service provider paid a $850,000 Mootness Fee to plaintiff’s counsel in full on the company’s behalf. The Court then granted an order closing the case, which will formally end after the Court is informed a quorum was achieved at the 2026 annual stockholders’ meeting scheduled for June 24, 2026.
Context Therapeutics Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 24, 2026 at 8:00 a.m. Eastern Time. Stockholders of record as of April 27, 2026, when 91,879,177 common shares were outstanding, may vote online or by proxy.
Investors are asked to elect seven directors for one-year terms, ratify CohnReznick LLP as independent auditor for 2026, and approve a charter amendment increasing authorized common stock from 200,000,000 to 300,000,000 shares to preserve flexibility for future financing, compensation and strategic uses. A separate proposal would allow adjournment of the meeting to solicit more proxies, particularly for the share increase, or to reach the 33 1/3% quorum required by Nasdaq rules.
The proxy statement also details board committee structures, independence determinations, risk oversight, insider trading and anti-hedging policies, and the background of directors and executive officers.
Context Therapeutics Inc. is soliciting proxies for its 2026 virtual Annual Meeting to be held June 24, 2026 with a record date of April 27, 2026. Agenda items include election of seven directors, ratification of CohnReznick LLP as auditor, and a charter amendment to increase authorized common shares from 200,000,000 to 300,000,000. The proxy materials are being delivered under SEC "notice and access" and final voting results will be filed on Form 8-K within four business days after the meeting.
Context Therapeutics Inc. reported that the FDA has granted Fast Track designation to CTIM-76, its investigational Claudin 6 x CD3 T cell engaging bispecific antibody, for treating platinum-resistant ovarian cancer in patients who have received all standard therapies.
CTIM-76 is being studied in a Phase 1 clinical trial in CLDN6-positive advanced or metastatic ovarian, endometrial and testicular cancers, assessing safety, tolerability, pharmacokinetics and anti-tumor activity. The company expects interim Phase 1a data for CTIM-76 in June 2026, highlighting a near-term clinical milestone for this program.
Context Therapeutics Inc. provided an updated corporate presentation outlining its strategy to build a leading T‑cell engager (TCE) pipeline for solid tumors and confirming an expected cash runway into mid‑2027. The company is advancing three CD3‑engaging bispecific antibodies: CTIM‑76 targeting Claudin 6, CT‑95 targeting mesothelin, and CT‑202 targeting Nectin‑4, all aimed at large relapse/refractory patient populations in ovarian, pancreatic, lung, bladder and other cancers.
CTIM‑76 is in an ongoing Phase 1a trial in CLDN6‑positive ovarian, endometrial and testicular cancers. As of October 2025, 12 heavily pretreated patients were enrolled, with linear pharmacokinetics, dose‑responsive T‑cell activity, no dose‑limiting toxicities, no cytokine release syndrome above Grade 1, and one confirmed partial response showing an 85% tumor reduction in platinum‑resistant ovarian cancer; interim Phase 1a data are anticipated in June 2026.
CT‑95 started a Phase 1a/1b dose‑escalation study in multiple mesothelin‑expressing tumors, with interim Phase 1a data expected in September 2026. CT‑202 remains preclinical, using pH‑dependent, avidity‑enhanced design to concentrate activity in the tumor microenvironment, with first patient dosing in a Phase 1 trial planned for the third quarter of 2026. Across the portfolio, preclinical models show selective tumor cell killing with efforts to reduce cytokine release and off‑tumor toxicity.
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company developing T cell engaging bispecific antibodies for solid tumors, centered on three programs: CTIM-76, CT-95 and CT-202.
CTIM-76, a Claudin 6 x CD3 engager, is in a Phase 1 dose-escalation and expansion trial, with the first patient dosed in January 2025 and Phase 1a interim data expected in June 2026. CT-95, a Mesothelin x CD3 engager acquired for $3.75 million, entered Phase 1 in April 2025, with Phase 1a interim data targeted for September 2026. CT-202, a Nectin-4 x CD3 engager in-licensed from BioAtla for an $11.0 million upfront payment plus milestones and royalties, is preclinical; an application was submitted in March 2026 to the Australian HREC, and first dosing in a Phase 1 trial is planned for the third quarter of 2026.
The company emphasizes significant market opportunities in CLDN6-, MSLN- and Nectin-4–positive relapsed/refractory cancers, retains broad global rights to key patents, and relies on third-party manufacturers and licensors. It highlights substantial ongoing capital needs, dependence on successful clinical development and regulatory approvals, competition from other oncology developers, intellectual property uncertainties and the risk of not maintaining Nasdaq listing requirements.
Context Therapeutics Inc. reports governance changes following a Delaware Court of Chancery ruling on a stockholder class action. On March 11, 2026, the court approved a stipulated judgment declaring charter provisions that set three-year director terms and removal only for cause invalid and unenforceable. The company filed a Certificate of Correction removing these provisions from its charter.
As a result, the current directors’ terms will expire at the 2026 annual meeting of stockholders, and directors may now be removed with or without cause by a majority of shares entitled to vote. The class action was dismissed with prejudice as to the plaintiff. The 2026 annual meeting is scheduled for June 24, 2026, with a record date of April 27, 2026, and the company plans to propose election of director nominees to one-year terms.
Context Therapeutics Inc. filed an agreement to resolve a Delaware stockholder class action by asking the court to invalidate two charter provisions that gave directors three-year terms and allowed removal only for cause. If the court approves the stipulated judgment, these governance provisions will be removed through a Certificate of Correction.
The case would then be dismissed with prejudice, and the company plans to hold its 2026 annual meeting of stockholders on June 24, 2026, with a record date of April 27, 2026. Stockholders must submit proposals or director nominations by 5:00 p.m. EDT on March 14, 2026, and any stockholders using universal proxy rules to solicit for alternate director nominees must give notice by April 13, 2026.
Levit Alex C. reported acquisition or exercise transactions in this Form 4 filing.
Context Therapeutics Inc. reported that Chief Legal Officer and Corporate Secretary Alex C. Levit received a grant of stock options covering 270,000 shares on February 19, 2026. According to the terms, 25% of the options vest on February 19, 2027, with the remainder vesting in equal monthly installments over the following three years, conditioned on continued service.